PDF(Pubmed)
Abstract：
UNASSIGNED: Pregnant women manifest an increased risk of developing coagulation disorders. Unfractionated heparin (HEP) and low-molecular-weight heparin (LMWHep) are considered as selective medication in the case of pregnancy which needs anticoagulant treatment. In addition to anticoagulant properties, HEP and its derivatives manifest other properties including anti-cancer potential. According to Globocan\'s latest data, colorectal cancer (CRC) is the second most encountered form of malignancy in the case of women, manifesting some special particularities, as confusion of symptoms from cancer with symptoms encountered normally in pregnant women (such as constipation or rectal bleeding), delayed diagnosis because of limitations imposed both for the fetus and for the mother, and the need for special treatment.
UNASSIGNED: The aim of the present work is to follow the incidence and safety of consumption of HEP and LMWHep in the case of pregnant women and to analyze their potential on the HCT 116 colorectal carcinoma cells.
UNASSIGNED: Analyzing the consumption of heparins in case of pregnant women hospitalized from 01.01.2022 to 31.12.2022 at the Pius Brînzeu\" Emergency Clinical Hospital from Timisoara, Obstetrics and Gynecology Clinic I, it was observed that 44,6% of the patients were administered the following medication and no administration risks were observed. When tested on HCT 116 cells, heparins manifested a significant anti-migratory effect (with wound healing rates of 2,6%, when tested with HEP 100 UI concentration and 14.52% wound healing rates in case of fraxiparine 100 UI). In addition, different signs of apoptosis were observed, suggesting the pro-apoptotic potential of the tested substances.
UNASSIGNED: Heparins remain the preferred medication to be administered to pregnant women with the potential for coagulation disorders, showing a high safety profile. Testing on the cancerous line of colorectal carcinoma highlights important properties that stimulate future studies, to establish the anti-tumor potential and the exact mechanism of action.
UNASSIGNED: The aim of the present work is to follow the incidence and safety of consumption of HEP and LMWHep in the case of pregnant women and to analyze their potential on the HCT 116 colorectal carcinoma cells.
UNASSIGNED: Analyzing the consumption of heparins in case of pregnant women hospitalized from 01.01.2022 to 31.12.2022 at the Pius Brînzeu\" Emergency Clinical Hospital from Timisoara, Obstetrics and Gynecology Clinic I, it was observed that 44,6% of the patients were administered the following medication and no administration risks were observed. When tested on HCT 116 cells, heparins manifested a significant anti-migratory effect (with wound healing rates of 2,6%, when tested with HEP 100 UI concentration and 14.52% wound healing rates in case of fraxiparine 100 UI). In addition, different signs of apoptosis were observed, suggesting the pro-apoptotic potential of the tested substances.
UNASSIGNED: Heparins remain the preferred medication to be administered to pregnant women with the potential for coagulation disorders, showing a high safety profile. Testing on the cancerous line of colorectal carcinoma highlights important properties that stimulate future studies, to establish the anti-tumor potential and the exact mechanism of action.
摘要：
孕妇出现凝血障碍的风险增加。普通肝素（HEP）和低分子量肝素（LMWHEp）在需要抗凝治疗的妊娠情况下被认为是选择性药物。除了抗凝血性能，HEP及其衍生物表现出其他性质,包括抗癌潜力。根据Globocan的最新数据，结直肠癌（CRC）是女性第二常见的恶性肿瘤，表现出一些特殊的特点，由于癌症症状与孕妇通常遇到的症状（如便秘或直肠出血）混淆，由于对胎儿和母亲的限制而延迟诊断，需要特殊治疗。
■本项工作的目的是追踪孕妇服用HEP和LMWHep的发生率和安全性，并分析其对HCT116结直肠癌细胞的潜力。
■分析从01.01.2022到31.12.2022住院的孕妇在提米什瓦拉紧急临床医院的肝素消耗量，妇产科诊所I,观察到44,6%的患者接受了以下药物治疗,未观察到用药风险.在HCT116细胞上测试时，肝素表现出显着的抗迁移作用（伤口愈合率为2,6％，当用HEP100UI浓度测试时，在使用Fraxiparine100UI的情况下，伤口愈合率为14.52％）。此外,观察到不同的细胞凋亡迹象，提示测试物质的促凋亡潜力。
■肝素仍然是有凝血障碍的孕妇的首选药物。显示出较高的安全性。对大肠癌癌系的检测突出了刺激未来研究的重要特性，建立抗肿瘤潜力和确切的作用机制。
■本项工作的目的是追踪孕妇服用HEP和LMWHep的发生率和安全性，并分析其对HCT116结直肠癌细胞的潜力。
■分析从01.01.2022到31.12.2022住院的孕妇在提米什瓦拉紧急临床医院的肝素消耗量，妇产科诊所I,观察到44,6%的患者接受了以下药物治疗,未观察到用药风险.在HCT116细胞上测试时，肝素表现出显着的抗迁移作用（伤口愈合率为2,6％，当用HEP100UI浓度测试时，在使用Fraxiparine100UI的情况下，伤口愈合率为14.52％）。此外,观察到不同的细胞凋亡迹象，提示测试物质的促凋亡潜力。
■肝素仍然是有凝血障碍的孕妇的首选药物。显示出较高的安全性。对大肠癌癌系的检测突出了刺激未来研究的重要特性，建立抗肿瘤潜力和确切的作用机制。
